CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice

Clinical Cancer Research

Volumn 12, Issue 16, 2006, Pages 4908-4915

  Xin, Xiaohua ^a   Abrams, Tinya J ^a   Hollenbach, Paul W ^a   Rendahl, Katherine G ^a   Tang, Yan ^a   Oei, Yoko A ^a   Embry, Millicent G ^a   Swinarski, Debbie E ^a   Garrett, Evelyn N ^a   Pryer, Nancy K ^a   Trudel, Suzanne ^b   Jallal, Bahija ^a   Mendel, Dirk B ^a   Heise, Carla C ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHIR 258; FIBROBLAST GROWTH FACTOR RECEPTOR 3; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; ENZYME INHIBITION; EXPERIMENTAL MODEL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; BENZIMIDAZOLES; CELL GROWTH PROCESSES; CELL LINE, TUMOR; ENZYME INHIBITORS; HUMANS; MEMBRANE PROTEINS; MICE; MICE, SCID; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MULTIPLE MYELOMA; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; QUINOLONES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33748349241     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0957     Document Type: Article

References (20)

1. Bergsagel PL, Kuehl WM. Chromosome translocations in multiple myeloma. Oncogene 2001;20:5611-22.
2. Chesi M, Nardini E, Lim RS, Smith KD, Kuehl WM, Bergsagel PL. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood 1998;92:3025-34.
3. Malgeri U, Baldini L, Perfetti V, et al. Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by reverse transcription- polymerase chain reaction analysis of IGH-MMSET fusion transcripts. Cancer Res 2000;60:4058-61.
4. Chesi M, Brents LA, Ely SA, et al. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood 2001;97:729-36.
5. Otsuki T, Yamada O, Yata K, et al. Expression of fibroblast growth factor and FGF-receptor family genes in human myeloma cells, including lines possessing t(4;14)(q16.3;q32. 3) and FGFR3 translocation. Int J Oncol 1999;15:1205-12.
6. Li Z, Zhu YX, Plowright EE, et al. The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells. Blood 2001;97:2413-9.
7. Trudel S, Ely S, Farooqui Y, et al. Inhibition of FGFR3 induces terminal differentiation and apoptosis in t(4:14) myeloma. Blood 2004;103:3521-8.
8. Hideshima T, Chauhan D, Richardson P, Anderson KC. Identification and validation of novel therapeutic targets for multiple myeloma. J Clin Oncol 2005;23:6345-50.
9. Lee SH, Lopes de Menezes D, Vora J, et al. In vivo target modulation and biological activity of CHIR-258, a multi-targeted growth factor receptor kinase inhibitor, in colon cancer models. Clin Cancer Res 2005;11:3633-41.
10. Trudel S, Li ZH, Wei E, et al. CHIR-258, a novel, multi-targeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 2005;105:2941-8.
11. Lopes de Menezes DE, Peng J, Garrett EN, et al. CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia. Clin Cancer Res 2005;11:5281-91.
12. Epstein J, Yaccoby S. The SCID-hu myeloma model. Methods Mol Med 2005;113:183-90.
13. Tassone P, Neri P, Burger R, et al. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma. Clin Cancer Res 2005;11:4251-8.
14. Mitsiades CS, Mitsiades NS, Bronson RT, et al. Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications. Cancer Res 2003;63:6689-96.
15. Barton BE, Cullison J, Jackson J, Murphy T. A model that reproduces syndromes associated with human multiple myeloma in nonirradiated SCID mice. Proc Soc Exp Biol Med 2000;223:190-7.
16. Miyakawa Y, Ohnishi Y, Tomisawa M, et al. Establishment of a new model of human multiple myeloma using NOD/SCID/γc (null) (NOG) mice. Biochem Biophys Res Commun 2004;313:258-62.
17. Namba M, Ohtsuki T, Mori M, et al. Establishment of five human myeloma cell lines. In Vitro Cell Dev Biol 1989;25:723-9.
18. LeBlanc R, Catley LP, Hideshima T, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002;62:4996-5000.
19. Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005;16:139-49.
20. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111:1287-95.